{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:26:54Z","timestamp":1793424414551,"version":"4.5.0"},"reference-count":36,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91214103"],"award-info":[{"award-number":["91214103"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (\n                      <jats:italic>CFTR<\/jats:italic>\n                      ) gene. Recent therapies enable effective restoration of CFTR function of the most common F508del\n                      <jats:italic>CFTR<\/jats:italic>\n                      mutation. This shifts the unmet clinical need towards people with rare\n                      <jats:italic>CFTR<\/jats:italic>\n                      mutations such as nonsense mutations, of which G542X and W1282X are most prevalent. CFTR function measurements in patient-derived cell-based assays played a critical role in preclinical drug development for CF and may play an important role to identify new drugs for people with rare\n                      <jats:italic>CFTR<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here, we miniaturised the previously described forskolin-induced swelling (FIS) assay in intestinal organoids from a 96-well to a 384-well plate screening format. Using this novel assay, we tested CFTR increasing potential of a 1400-compound Food and Drug Administration (FDA)-approved drug library in organoids from donors with W1282X\/W1282X\n                      <jats:italic>CFTR<\/jats:italic>\n                      nonsense mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 384-well FIS assay demonstrated uniformity and robustness based on coefficient of variation and Z\u2019-factor calculations. In the primary screen, CFTR induction was limited overall, yet interestingly, the top five compound combinations that increased CFTR function all contained at least one statin. In the secondary screen, we indeed verified that four out of the five statins (mevastatin, lovastatin, simvastatin and fluvastatin) increased CFTR function when combined with CFTR modulators. Statin-induced CFTR rescue was concentration-dependent and W1282X-specific.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Future studies should focus on elucidating genotype specificity and mode-of-action of statins in more detail. This study exemplifies proof of principle of large-scale compound screening in a functional assay using patient-derived organoids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00495-2022","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T08:40:14Z","timestamp":1671698414000},"page":"00495-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing"],"prefix":"10.1183","volume":"9","author":[{"given":"Sacha","family":"Spelier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyleen","family":"de Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia N.","family":"Ithakisiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia W.F.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marne C.","family":"Hagemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danya","family":"Muilwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelotte M.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse E.","family":"Brunsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Kruisselbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis K.","family":"van der Ent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"2024101711452805000_9.1.00495-2022.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.03.011"},{"key":"2024101711452805000_9.1.00495-2022.2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2745"},{"key":"2024101711452805000_9.1.00495-2022.3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"2024101711452805000_9.1.00495-2022.4","doi-asserted-by":"publisher","DOI":"10.1021\/jm801640k"},{"key":"2024101711452805000_9.1.00495-2022.5","doi-asserted-by":"publisher","DOI":"10.1038\/nature05756"},{"key":"2024101711452805000_9.1.00495-2022.6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101711452805000_9.1.00495-2022.7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024101711452805000_9.1.00495-2022.8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024101711452805000_9.1.00495-2022.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468"},{"key":"2024101711452805000_9.1.00495-2022.10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3201"},{"key":"2024101711452805000_9.1.00495-2022.11","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"2024101711452805000_9.1.00495-2022.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.068"},{"key":"2024101711452805000_9.1.00495-2022.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00508-2021"},{"key":"2024101711452805000_9.1.00495-2022.14","doi-asserted-by":"crossref","unstructured":"Chai SC , Goktug AN , Chen T . Assay validation in high throughput screening: from concept to application. In: Vallisuta O, Olimat S, eds. Drug Discovery and Development \u2013 From Molecules to Medicine. London, IntechOpen, 2015; pp. 221\u2013239.","DOI":"10.5772\/59765"},{"key":"2024101711452805000_9.1.00495-2022.15","doi-asserted-by":"publisher","DOI":"10.1177\/108705719900400206"},{"key":"2024101711452805000_9.1.00495-2022.16","unstructured":"CFTR2. Database UCF. The Clinical and Functional TRanslation of CFTR (CFTR2). http:\/\/cftr2.org Date last updated: 29 April 2022. Date last accessed: 24 September 2022."},{"key":"2024101711452805000_9.1.00495-2022.17","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.9.6.1235-1239.2002"},{"key":"2024101711452805000_9.1.00495-2022.18","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.183"},{"key":"2024101711452805000_9.1.00495-2022.19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2018.03.040","article-title":"Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency","volume":"155","author":"van Rijn","year":"2018","journal-title":"Gastroenterology"},{"key":"2024101711452805000_9.1.00495-2022.20","doi-asserted-by":"crossref","first-page":"L1286","DOI":"10.1152\/ajplung.00127.2003","article-title":"Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells","volume":"285","author":"Kreiselmeier","year":"2003","journal-title":"Am J Physiol Cell Mol Physiol"},{"key":"2024101711452805000_9.1.00495-2022.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2024101711452805000_9.1.00495-2022.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.11.010"},{"key":"2024101711452805000_9.1.00495-2022.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-016-0009-6"},{"key":"2024101711452805000_9.1.00495-2022.24","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjaa036"},{"key":"2024101711452805000_9.1.00495-2022.25","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.stemcr.2021.09.020","article-title":"A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients","volume":"16","author":"Jiang","year":"2021","journal-title":"Stem Cell Rep"},{"key":"2024101711452805000_9.1.00495-2022.26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/2472555219849375","article-title":"High-throughput surface liquid absorption and secretion assays to identify F508del CFTR correctors using patient primary airway epithelial cultures","volume":"24","author":"Berg","year":"2019","journal-title":"SLAS Discov"},{"key":"2024101711452805000_9.1.00495-2022.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02529-2017"},{"key":"2024101711452805000_9.1.00495-2022.28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8278"},{"key":"2024101711452805000_9.1.00495-2022.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024101711452805000_9.1.00495-2022.30","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2010.0313"},{"key":"2024101711452805000_9.1.00495-2022.31","unstructured":"Bansal AB , Cassagnol M . HMG-CoA Reductase Inhibitors. In: StatPearls [Internet]. Treasure Island, FL, StatPearls Publishing. Available from: www.ncbi.nlm.nih.gov\/books\/NBK542212\/ Date last updated: 4 July 2022."},{"key":"2024101711452805000_9.1.00495-2022.32","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S87979"},{"key":"2024101711452805000_9.1.00495-2022.33","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/cells8080804","article-title":"Cholesterol interaction directly enhances intrinsic activity of the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"8","author":"Chin","year":"2019","journal-title":"Cells"},{"key":"2024101711452805000_9.1.00495-2022.34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00003495-198800363-00016","article-title":"Mechanism of action and biological profile of HMG CoA reductase inhibitors","volume":"36: Suppl 3","author":"Slater","year":"1988","journal-title":"Drugs"},{"key":"2024101711452805000_9.1.00495-2022.35","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamcr.2015.04.010","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2024101711452805000_9.1.00495-2022.36","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1093\/nar\/gkab882","article-title":"A role for AKT1 in nonsense-mediated mRNA decay","volume":"49","author":"Palma","year":"2021","journal-title":"Nucleic Acids Res"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00495-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:22:35Z","timestamp":1740356555000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00495-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,30]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1183\/23120541.00495-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00495-2022","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.14.500147","asserted-by":"object"}]},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}